Bio-Pharmaceutical complex wages war against respiratory syncytial virus

Respiratory Syncytial Virus (RSV) and the Use of Nurse of a Map

Respiratory Syncytial Virus (RSV) is a common viral infection, particularly affecting children under one year old. The bio-pharmaceutical industry has developed a monoclonal antibody called nurse of a map, or Bayfortis, to prevent RSV. However, there are concerns regarding its efficacy and safety. Clinical trials showed no significant reduction in hospitalization rates, and there have been reports of adverse effects, including bronchiolitis. In France, nurse of a map has been rolled out as a standard treatment for newborns, despite indications of an increased mortality rate. The financial incentives offered by pharmaceutical companies to hospitals and midwives for administering nurse of a map raise concerns about transparency and potential corruption. There is a need for further investigations into the risks and benefits of this monoclonal antibody.